Skip to main content

Table 1 Patient characteristics in the case-control series: patients with extracted RNA sample

From: Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study

   V cases V controls BV cases BV controls B cases B controls
Number of patients   246 232 258 245 238 222
   Number (%)      
Age at hist. diagnosis Median (years) 57.1 51.5 55.7 51.0 55.9 51.2
Grade 1 11 (4%) 33 (14%) 7 (3%) 36 (15%) 20 (8%) 20 (9%)
  2 81 (33%) 89 (38%) 113 (44%) 127 (52%) 114 (48%) 97 (44%)
  3 135 (55%) 87 (38%) 122 (47%) 62 (25%) 81 (34%) 88 (40%)
  Unknown 19 (8%) 23 (10%) 16 (6%) 20 (8%) 23 (10%) 17 (8%)
ER IHC status Positive 147 (60%) 160 (69%) 162 (63%) 174 (71%) 188 (79%) 158 (71%)
  Negative 99 (40%) 72 (31%) 96 (37%) 71 (29%) 50 (21%) 64 (29%)
PR status Positive 97 (39%) 121 (52%) 116 (45%) 131 (53%) 146 (61%) 113 (51%)
  Negative 149 (61%) 111 (48%) 142 (55%) 114 (47%) 92 (39%) 109 (49%)
HER2 status Positive 58 (24%) 35 (15%) 55 (21%) 30 (12%) 35 (15%) 23 (10%)
  Negative 108 (44%) 102 (44%) 116 (45%) 98 (40%) 108 (45%) 107 (48%)
  Unknown 80 (33%) 95 (41%) 87 (34%) 117 (48%) 95 (40%) 92 (41%)
Tumour size <= 2 cm 96 (40%) 113 (49%) 99 (38%) 136 (56%) 101 (42%) 117 (53%)
  >2 cm 146 (60%) 113 (49%) 155 (60%) 101 (41%) 133 (56%) 99 (45%)
  Unknown -- -- 6 (3%) 4 (2%) 8 (3%) 4 (2%) 6 (3%)
Lymph nodes positive 0 51 (21%) 97 (42%) 61 (24%) 109 (44%) 61 (26%) 103 (46%)
  1–3 74 (30%) 81 (35%) 64 (25%) 80 (33%) 70 (29%) 64 (29%)
  4+ 74 (30%) 28 (12%) 81 (31%) 28 (11%) 64 (27%) 29 (13%)
  Unknown 47 (19%) 26 (11%) 52 (20%) 28 (11%) 43 (18%) 26 (12%)
Invasive subtype NOS/no special type 217 (88%) 189 (81%) 219 (85%) 206 (84%) 196 (82%) 189 (85%)
  Ductal - mucinous 1 (0%) 3 (1%) 4 (2%) 2 (1%) 1 (0%) 4 (2%)
  Ductal - tubular -- -- 6 (3%) 1 (0%) 7 (3%) 3 (1%) 3 (1%)
  Ductal - other 6 (2%) 3 (1%) 1 (0%) 3 (1%) 1 (0%) 3 (1%)
  Lobular - classical 14 (6%) 23 (10%) 19 (7%) 22 (9%) 29 (12%) 13 (6%)
  Lobular - pleomorphic 3 (1%) 2 (1%) 6 (2%) 3 (1%) 3 (1%) 4 (2%)
  Lobular - other 2 (1%) 3 (1%) 3 (1%) 2 (1%) 4 (2%) 1 (0%)
  Other 3 (1%) 3 (1%) 5 (2%) -- -- 1 (0%) 5 (2%)
Surgery type (any time) Breast conserving 58 (24%) 80 (34%) 70 (27%) 82 (33%) 64 (27%) 72 (32%)
  Breast conserving + mastectomy 53 (22%) 28 (12%) 56 (22%) 32 (13%) 37 (16%) 27 (12%)
  Mastectomy 106 (43%) 110 (47%) 99 (38%) 120 (49%) 115 (48%) 114 (51%)
  Unknown 29 (12%) 14 (6%) 33 (13%) 11 (4%) 22 (9%) 9 (4%)
Radiotherapy (adj/neo) Yes 168 (68%) 140 (60%) 197 (76%) 126 (51%) 194 (82%) 125 (56%)
  No 78 (32%) 92 (40%) 61 (24%) 119 (49%) 44 (18%) 97 (44%)
Hormone treatment (adj/neo) Yes 204 (83%) 120 (52%) 230 (89%) 130 (53%) 218 (92%) 114 (51%)
  No 42 (17%) 112 (48%) 28 (11%) 115 (47%) 20 (8%) 108 (49%)
Chemotherapy Neo-adj only -- -- 3 (1%) 3 (1%) 67 (27%) 8 (3%) 3 (1%)
  Neo-adj and adj 6 (2%) 1 (0%) 9 (3%) 1 (0%) 1 (0%) 2 (1%)
  Adj only 146 (59%) 85 (37%) 150 (58%) 2 (1%) 101 (42%) 67 (30%)
  No 94 (38%) 143 (62%) 96 (37%) 175 (71%) 128 (54%) 150 (68%)
  1. Hist. histological assessment, ER IHC estrogen receptor status determined by immunohistochemical assessment, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, adj adjuvant, neo neoadjuvant